Low-dose total-body irradiation and alemtuzumab-based reduced-intensity conditioning regimen results in durable engraftment and correction of clinical disease among children with chronic granulomatous disease

Bhakti Mehta, Kris Mahadeo, Neena Kapoor, Hisham Abdel-Azim

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

HSCT with MAC is associated with durable donor engraftment for patients with CGD; however, MAC is limited by high rates of RRT. We used a novel RIC regimen with LD-TBI (200 cGy × two doses), fludarabine (30 mg/m<sup>2</sup> × three doses), and proximal alemtuzumab (0.5 mg/kg/dose × one dose) and unrelated donor grafts for consecutive patients with high-risk CGD who were not candidates for MAC at our institution. Among four children with CGD transplanted at our institution, three PBSC recipients are alive with sustained donor engraftment (median follow-up: two yr) and resolution of pre-HSCT active infections while one patient with bone marrow graft is alive after graft failure and autologous recovery. RIC may be a curative option for children with high-risk CGD.

Original languageEnglish (US)
Pages (from-to)408-412
Number of pages5
JournalPediatric Transplantation
Volume19
Issue number4
DOIs
StatePublished - Jun 1 2015

Fingerprint

Chronic Granulomatous Disease
Whole-Body Irradiation
Transplants
Tissue Donors
Unrelated Donors
Bone Marrow
Infection
alemtuzumab

Keywords

  • chronic granulomatous disease
  • hematopoietic stem cell transplantation
  • pediatric
  • reduced-intensity conditioning
  • unrelated donor

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Transplantation

Cite this

Low-dose total-body irradiation and alemtuzumab-based reduced-intensity conditioning regimen results in durable engraftment and correction of clinical disease among children with chronic granulomatous disease. / Mehta, Bhakti; Mahadeo, Kris; Kapoor, Neena; Abdel-Azim, Hisham.

In: Pediatric Transplantation, Vol. 19, No. 4, 01.06.2015, p. 408-412.

Research output: Contribution to journalArticle

@article{90630019e08f40e2b94d9d45a0d1a8a8,
title = "Low-dose total-body irradiation and alemtuzumab-based reduced-intensity conditioning regimen results in durable engraftment and correction of clinical disease among children with chronic granulomatous disease",
abstract = "HSCT with MAC is associated with durable donor engraftment for patients with CGD; however, MAC is limited by high rates of RRT. We used a novel RIC regimen with LD-TBI (200 cGy × two doses), fludarabine (30 mg/m2 × three doses), and proximal alemtuzumab (0.5 mg/kg/dose × one dose) and unrelated donor grafts for consecutive patients with high-risk CGD who were not candidates for MAC at our institution. Among four children with CGD transplanted at our institution, three PBSC recipients are alive with sustained donor engraftment (median follow-up: two yr) and resolution of pre-HSCT active infections while one patient with bone marrow graft is alive after graft failure and autologous recovery. RIC may be a curative option for children with high-risk CGD.",
keywords = "chronic granulomatous disease, hematopoietic stem cell transplantation, pediatric, reduced-intensity conditioning, unrelated donor",
author = "Bhakti Mehta and Kris Mahadeo and Neena Kapoor and Hisham Abdel-Azim",
year = "2015",
month = "6",
day = "1",
doi = "10.1111/petr.12471",
language = "English (US)",
volume = "19",
pages = "408--412",
journal = "Pediatric Transplantation",
issn = "1397-3142",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Low-dose total-body irradiation and alemtuzumab-based reduced-intensity conditioning regimen results in durable engraftment and correction of clinical disease among children with chronic granulomatous disease

AU - Mehta, Bhakti

AU - Mahadeo, Kris

AU - Kapoor, Neena

AU - Abdel-Azim, Hisham

PY - 2015/6/1

Y1 - 2015/6/1

N2 - HSCT with MAC is associated with durable donor engraftment for patients with CGD; however, MAC is limited by high rates of RRT. We used a novel RIC regimen with LD-TBI (200 cGy × two doses), fludarabine (30 mg/m2 × three doses), and proximal alemtuzumab (0.5 mg/kg/dose × one dose) and unrelated donor grafts for consecutive patients with high-risk CGD who were not candidates for MAC at our institution. Among four children with CGD transplanted at our institution, three PBSC recipients are alive with sustained donor engraftment (median follow-up: two yr) and resolution of pre-HSCT active infections while one patient with bone marrow graft is alive after graft failure and autologous recovery. RIC may be a curative option for children with high-risk CGD.

AB - HSCT with MAC is associated with durable donor engraftment for patients with CGD; however, MAC is limited by high rates of RRT. We used a novel RIC regimen with LD-TBI (200 cGy × two doses), fludarabine (30 mg/m2 × three doses), and proximal alemtuzumab (0.5 mg/kg/dose × one dose) and unrelated donor grafts for consecutive patients with high-risk CGD who were not candidates for MAC at our institution. Among four children with CGD transplanted at our institution, three PBSC recipients are alive with sustained donor engraftment (median follow-up: two yr) and resolution of pre-HSCT active infections while one patient with bone marrow graft is alive after graft failure and autologous recovery. RIC may be a curative option for children with high-risk CGD.

KW - chronic granulomatous disease

KW - hematopoietic stem cell transplantation

KW - pediatric

KW - reduced-intensity conditioning

KW - unrelated donor

UR - http://www.scopus.com/inward/record.url?scp=84929045653&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929045653&partnerID=8YFLogxK

U2 - 10.1111/petr.12471

DO - 10.1111/petr.12471

M3 - Article

VL - 19

SP - 408

EP - 412

JO - Pediatric Transplantation

JF - Pediatric Transplantation

SN - 1397-3142

IS - 4

ER -